Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal.
Bristol Myers Squibb (BMY.N) on Friday agreed to buy Karuna Therapeutics ( NASDAQ:KRTX ) for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older therapies expire later this decade.
Karuna's experimental schizophrenia...
